No Role for Cerebrospinal Fluid Myelin Basic Protein Levels in Patients Treated for Childhood Acute Lymphoblastic Leukemia.

Details

Ressource 1Request a copy Sous embargo indéterminé.
State: Public
Version: Final published version
License: All rights reserved
Serval ID
serval:BIB_205B700905E7
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
No Role for Cerebrospinal Fluid Myelin Basic Protein Levels in Patients Treated for Childhood Acute Lymphoblastic Leukemia.
Journal
Journal of Pediatric Hematology/Oncology
Author(s)
Diezi M., Garcia E., Weid N., Beck-Popovic M.
ISSN
1536-3678[electronic]
Publication state
Published
Issued date
2009
Volume
31
Number
6
Pages
393-397
Language
english
Abstract
INTRODUCTION: Central nervous system prophylaxis of childhood acute lymphoblastic leukemia has dropped rates of relapses but has been associated with neurotoxicity and imaging abnormalities. Predictors of neurotoxicity are lacking, because of inconsistency between clinical symptoms and imaging. Some have suggested that cerebrospinal fluid myelin basic protein (MBP) levels to be of potential interest. A retrospective analysis of MBP levels in correlation with clinical and radiologic data is presented. MATERIALS AND METHODS: MBP levels obtained at the time of intrathecals, charts, and neuroradiology reports were retrospectively analyzed. Academic achievement data were obtained from phone contacts with patients and families. RESULTS: We retrieved 1248 dosages of MBP in 83 patients, 381 neurologic examinations in 34 patients and 69 neuroradiologic investigations in 27 patients. Fifty-two patients had abnormal MBP levels. Radiologic anomalies were present in 47% of those investigated, 14% of them having school difficulties. Proportions of patients with school difficulties in the groups with abnormal MBP levels but no radiologic anomalies or with no radiologic investigations were 0% and 3%, respectively, which was lower than in the group of patients with normal MBP levels (100%, 22%, and 5%, respectively). DISCUSSION: Notwithstanding the retrospective character of our study, we conclude that there is limited usefulness of systematic dosage of MBP as indicator of treatment-induced neurotoxicity in acute lymphoblastic leukemia patients.
Keywords
Adolescent, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Brain/pathology, Central Nervous System Neoplasms/prevention & control, Child, Child, Preschool, Cognition Disorders/cerebrospinal fluid, Cognition Disorders/etiology, Combined Modality Therapy/adverse effects, Cranial Irradiation, Female, Humans, Infant, Infant, Newborn, Injections, Spinal, Male, Myelin Basic Proteins/cerebrospinal fluid, Precursor Cell Lymphoblastic Leukemia-Lymphoma/cerebrospinal fluid, Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology
Pubmed
Web of science
Create date
29/09/2009 8:59
Last modification date
20/08/2019 12:56
Usage data